Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neutropenia 3Neoplasms 2Infections 2Hematologic Neoplasms 2Febrile Neutropenia 2Urinary Tract Infections 1Staphylococcal Infections 1Spasm 1Sleep Initiation and Maintenance Disorders 1Sepsis 1Seizures 1Schizophrenia, Treatment-Resistant 1Schizophrenia 1Retinitis 1Renal Insufficiency, Chronic 1Pulmonary Arterial Hypertension 1Pneumonia 1Pain 1Migraine Disorders 1Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1Menorrhagia 1Meningitis, Bacterial 1Meningitis 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Intraabdominal Infections 1Influenza, Human 1Inflammation 1Hypokalemia 1Hypertension 1

Interventions

enzalutamide 2sipuleucel-T 1Vancomycin 1Metronidazole 1Docetaxel 1Ciprofloxacin 1Amoxicillin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Metastatic Castration-Resistant Prostate Cancer (mCRPC) × Vancomycin × Clear all
NCT06126731 2025-11-24

Combination Study of Antibiotics With Enzalutamide (PROMIZE)

Institute of Cancer Research, United Kingdom

Phase 1/2 Recruiting
39 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡